Mucocutaneous manifestations among adults hospitalized with multisystem inflammatory syndrome following SARS-CoV-2 infection
- PMID: 35098173
- PMCID: PMC8784576
- DOI: 10.1016/j.jdin.2022.01.005
Mucocutaneous manifestations among adults hospitalized with multisystem inflammatory syndrome following SARS-CoV-2 infection
Conflict of interest statement
Dr Garg has received honoraria from AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio and has served as an advisor for AbbVie, Amgen, Boehringer Ingelheim, Janssen, Pfizer, Incyte, InfalRx, Viela Bio, and UCB. Authors Tannenbaum, Strunk, Burshtein, Grbic, Nazir, and Norden and Drs Rekhtman, Birabaharan, Shaigany, Godfred-Cato, Belay, and Patel do not have any conflicts of interest to disclose.
References
-
- Wollins D.S., Belay E., Threlkeld M., Threlkeld S., Morris S.B. CDC/IDSA COVID-19 clinician call: multisystem inflammatory syndrome in adults (MIS-A); plus ACIP meeting update. https://www.idsociety.org/multimedia/clinician-calls/cdcidsa-covid-19-cl...
-
- Rekhtman S., Tannenbaum R., Strunk A., Birabaharan M., Wright S., Garg A. Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children. J Am Acad Dermatol. 2021;84(2):408–414. doi: 10.1016/j.jaad.2020.10.060. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous